RANIERI, Elena
 Distribuzione geografica
Continente #
NA - Nord America 501
EU - Europa 132
AS - Asia 62
Totale 695
Nazione #
US - Stati Uniti d'America 499
SE - Svezia 72
SG - Singapore 45
DE - Germania 19
CN - Cina 12
IT - Italia 12
FR - Francia 9
GB - Regno Unito 9
FI - Finlandia 5
IN - India 4
UA - Ucraina 4
CA - Canada 1
LT - Lituania 1
PH - Filippine 1
PR - Porto Rico 1
RO - Romania 1
Totale 695
Città #
Chandler 89
Nyköping 66
Fairfield 56
Singapore 40
Woodbridge 37
Ashburn 32
Houston 26
Seattle 22
Wilmington 20
New York 18
Cambridge 17
Lawrence 16
Roxbury 15
Inglewood 14
Munich 13
Ann Arbor 9
Paris 9
Des Moines 8
Jacksonville 6
San Diego 6
Bari 4
Helsinki 4
London 4
Santa Clara 4
Beijing 3
Los Angeles 3
Pune 3
Gioia del Colle 2
Norwalk 2
Princeton 2
San Mateo 2
Acton 1
Bitonto 1
Boardman 1
Chicago 1
Falkenstein 1
Guangzhou 1
Hebei 1
Islington 1
Jiaxing 1
Modugno 1
Mumbai 1
Nanjing 1
Ottawa 1
Pescara 1
Prescot 1
Saarbrücken 1
San Juan 1
Shanghai 1
Washington 1
Wuhan 1
Totale 572
Nome #
Modulation of complement activation by pentraxin-3 in prostate cancer. 70
Interferon-alpha (IFN-alpha) –conditioned DC Preferentially Stimulate Type-1 and Limit Treg-type In Vitro T-cell Responses From RCC Patients 66
Altered phosphorylation of cytoskeleton proteins in peripheral blood mononuclear cells characterizes chronic antibody-mediated rejection in kidney transplantation 56
Molecular Mechanisms of AKI in the Elderly: From Animal Models to Therapeutic Intervention 54
Recurrent Glomerulonephritis after Renal Transplantation: The Clinical Problem 50
IgE-Mediated Immune Response and Antibody-Mediated Rejection 47
CD40L proinflammatory and profibrotic effects on proximal tubular epithelial cells: Role of NF-κB and Lyn 46
PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma 44
Low C3 Serum Levels Predict Severe Forms of STEC-HUS With Neurologic Involvement 38
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand? 36
The ambivalent role of miRNAs in carcinogenesis: Involvement in renal cell carcinoma and their clinical applications 33
Pentraxin-3-mediated complement activation in a swine model of renal ischemia/reperfusion injury 32
Targeting Premature Renal Aging: from Molecular Mechanisms of Cellular Senescence to Senolytic Trials 26
mTOR inhibition improves mitochondria function/biogenesis and delays cardiovascular aging in kidney transplant recipients with chronic graft dysfunction 24
Thrombin may modulate dendritic cells activation in kidney transplant recipients with delayed graft function. 24
TLR-4 Signaling in Pericytes 21
Beyond pre-analytical and analytical concerns in the study of synovial fluid proteome: description of an optimized Gel-based protocol 17
Urinary epidermal growth factor/monocyte chemotactic peptide 1 ratio as non-invasive predictor of Mayo clinic imaging classes in autosomal dominant polycystic kidney disease 17
Role of complement in regulating inflammation processes in renal and prostate cancers 15
Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children 9
MUC1 Expression Affects the Immunoflogosis in Renal Cell Carcinoma Microenvironment through Complement System Activation and Immune Infiltrate Modulation 8
Unraveling the Link between Interferon-α and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies 5
Negative and positive separation techniques for the isolation of antigen-specific CD8+ T cells from blood and tumor tissue 4
Totale 742
Categoria #
all - tutte 6.652
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.652


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202023 0 0 0 0 3 1 3 2 5 1 4 4
2020/2021184 1 3 0 32 45 0 31 24 6 18 9 15
2021/2022111 11 1 0 0 3 13 1 4 30 6 25 17
2022/2023231 22 48 21 9 16 34 11 31 26 1 8 4
2023/202493 10 21 5 9 6 29 0 0 0 2 1 10
2024/202593 30 19 28 11 5 0 0 0 0 0 0 0
Totale 742